Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Universidad El Bosque · George Washington University · +51 more institutions
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA.
We conducted an observational, prospective cohort study of CRPA isolated from bloodstream, respiratory, urine, or wound cultures of patients at 44 hospitals (10 countries) between Dec 1, 2018, and Nov 30, 2019. Clinical data were abstracted from health records and CRPA isolates were whole-genome sequenced. The primary outcome was 30-day mortality from the day the index culture was collected. We compared outcomes of patients with CRPA infections by infection type and across geographic regions and performed an inverse probability weighted analysis to assess the association between carbapenemase production and 30-day mortality.
Citation impact
- FWCI
- 25.26
- Percentile
- 100%
- References
- 35
Authors
86Topics & keywords
- Pseudomonas aeruginosa
- Epidemiology
- Medicine
- Prospective cohort study
- Carbapenem
- Cohort study
- Cohort
- Microbiology
- Good health and well-being
Funding
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- GSGilead Sciences
- TPTeva Pharmaceutical Industries
- IDInfectious Diseases Society of America
- APAlexion Pharmaceuticals
- UOUniversity of Pennsylvania
- AAtriCure
- CWCase Western Reserve University
- RPRegeneron Pharmaceuticals
- CTCidara Therapeutics
- BDBioFire Diagnostics
- ETEntasis Therapeutics
- APApellis Pharmaceuticals
- MModerna
- STSeres Therapeutics
- CACombating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
- MSMeiji Seika Pharma
- APAstellas Pharma
- SShionogi
- WWockhardt
- TTTenNor Therapeutics
- NINational Institutes of HealthAwards: UM1 AI104681, AI104681
- GGenentech
- SSamsung
- AAllergan
- CPChugai Pharmaceutical
- BABiomedical Advanced Research and Development Authority
- FTFUJIFILM Toyama Chemical
- NINational Institute of Allergy and Infectious DiseasesAward: UM1 AI104681
- FNFondo Nacional de Desarrollo Científico y Tecnológico
- DODivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases